

Classification of Compounds as STOT-RE based on existing high throughput NAM data

Matthias Wehr¹, Barira Islam², Laura I. Furlong³, Jordi Valls-Margarit³, Jaione Telleria-Zufiaur³, Sylvia E. Escher¹ ¹ Fraunhofer Institute for Toxicology and Experimental Medicine; ² Certara UK; ³ Medbioinformatics Solutions SL


Hazard Assessment

(PBK)

kineti



The case study evaluates the applicability of existing NAM data to classify compounds as systemically toxic for specific target organ toxicity (STOT-RE) after repeated exposure.



Approach and Ressources

66 compounds (RHT3R CS 2) are classified as **STOT-RE** based on available in vivo animal studies; subchronic oral exposure (toxic <10 mg/kg bw/d; low toxic > 1000 mg/kg bw/d). The classification approach is developed using four data sources:

- **ToxCast dataset:** AC₅₀ values classified as "hits" from ToxCast database (DB) comprising about 1300 individual assays. Hits are AC50 values < cytotoxic levels. Excluded hit calls: outside of tested concentration range, data point flagged as noisy data by ToxCast. Borderline (in)active kept.
- **Chemical Effect Predictor (CEP)** uses a heterogeneous network combining chemicals, proteins, biological processes and diseases to predict drug-disease associations.
- **Physicochemical data** from PubChem and ChEMBL and predicted ADME parameters using ADMET predictor. Hepatic clearance data (*httk* DB) available for CAS 120-55-8.
- **Kinetics:** Simcyp[™] simulator was used to build **PBK models** of the compounds. Cmax and AUC predicted after single (24h)/repeated exposure (240h).

ToxCast dataset


Trainingset 46 cmpds (30 toxic, 16 low toxic)

Combined ranking of compounds results in best separation of low toxic and toxic compounds:

I) Frequency – number of hit calls in all assay is higher than 5%. Data rich compounds are considered to have a higher confidence in the prediction

II) Potency - the 10^{th} percentile of all AC₅₀ values is $< 5\mu M$

| Figure 1: Toxic compounds show a trend |
|--|
| toward more and sensitive hit calls |



CAS

Trainingset: 38 cmpds (28 toxic, 10 low toxic)

CEP predicts associated 7351 diseases per compound. The diseases with a predicted probability > 0.59 are considered associated diseases with the compound. A toxicity score is calculated per compounds:


Chemical Effect Predictor

ToxScore =

Proportion of pos. ass. diseases

Mean probability

The 1st quartile of the *High toxic* toxicity score (1.69 x 10⁻³) discriminated best low and toxic compounds.



| RAN | RANKING Toxic Low toxic | | Low toxic | | | | |
|--------|-------------------------|----|-----------|-------------------|--|--|--|
| ACTUAL | High toxic | 25 | 3 | Sensitivity: 0.89 | | | |
| | Low toxic | 1 | 8 | Specificity: 0.88 | | | |

PREDICTED

Kinetic Assessment

Internal exposure categorisation: In silico ADME data applied, except of CAS 120-55-8 to model Cmax and AUC after single or repeated exposure. All other compounds estimate **renal clearance** using a **conservative estimate** of fu*GFR

The categorisation of these compounds might change when exp liver clearance is added to the PBK models of these compounds, as ECCS classification¹ predicts it to be cleared by liver.

| CAS | Predicted Fa | Plasma Cmax (mg/L, 24 h) | Plasma Cmax (mg/L, 240 h) | AUC (24 h) | AUC (240 h) | ECCS | Internal Exposure Categorisation (single dose) |
|------------|--------------|-----------------------------|------------------------------|---------------|----------------|-----------|---|
| 96-26-4 | 0.96 | 16.2 | 16.07 | 100.06 | 101.56 | Class_2 | Low |
| 70-47-3 | 0.513 | 4.24 | 4.2 | 51.83 | 50.25 | Class_4 | Low |
| 134-03-2 | 0.314 | 3.15 | 3.49 | 43.26 | 48.21 | Class_3A | Low |
| 819-83-0 | 0.67 | 11.7 | 11.14 | 95.03 | 87.41 | Class_3A | Low |
| 693-23-2 | 0.99 | 102 | 165 | 1679.6 | 2649.6 | Class_1A | High* |
| 505-52-2 | 0.91 | 85.9 | 181.91 | 1653.41 | 3480.62 | Class_1A | High* |
| 3937-56-2 | 0.97 | 9.32 | 17.1 | 117.83 | 299.88 | Class_2 | Medium* |
| 504-63-2 | 0.98 | 1.94 | 1.75 | 96.69 | 106.34 | Class_2 | Low |
| 120-55-8 | 0.99 | 4.4 | 2.07 | 26.06 | 24.94 | Class_2 | Low |
| 27503-81-7 | 0.82 | 30.5 | 29.4 | 234.36 | 212.8 | Class_1A | Medium* |
| 33996-33-7 | 0.89 | 27.4 | 25.6 | 164.14 | 149.46 | Class_1A | Medium* |
| 98737 | 0.99 | 105 | 170.5 | 1711.86 | 2755.44 | Class_1A* | High |
| 61-90-5 | 0.94 | 18.4 | 18 | 119.17 | 110.75 | Class_1A | Low |
| 3047-32-3 | 0.99 | 28.6 | 18.6 | 125.99 | 117.07 | Class_2 | Low |
| 38517-37-2 | 0.72 | 71.5 | 241.7 | 1507.93 | 5297.59 | Class_3A | High |
| 667-84-5 | 0.81 | 11 | 10.8 | 97.63 | 91.38 | Class_4 | Low |
| 840-65-3 | 0.99 | 9.4 | 15.6 | 56.5 | 328.57 | Class_2 | Medium* |

and disease state (mean is shown)

Resulting Classification

- The toxic compound is classified correctly by either method
- Overestimate hazard in several cases, for which hepatic clearance is likely underpredicted at the moment

| | Hazard (ToxCast) | | | Hazard (CEP) | | | |
|--------|------------------------|--------|-----------|------------------------|--------|-------------|--|
| | low | middle | high | low | middle | high | |
| | | | | 61-90-5 | | | |
| low | 134-03-2 | | 120-55-8 | 70-47-3 | | | |
| | | | | 96-26-4 | | 120-55-8 | |
| | 27503-81-7* | | | | | 840-65-3* | |
| middle | 33996-33-7* | | 840-65-3* | | | 27503-81-7* | |
| | 693-23-2* | | | | | | |
| | <mark>505-52-2*</mark> | | | <mark>693-23-2*</mark> | | | |
| high | <mark>98-73-7</mark> | | | 98-73-7 | | 505-52-2* | |

Next steps

- Closer look into outliers and their mode of action
- Integrate Tier 2 data from CS2; evaluate machine learning approaches
- Measure hepatic Clint values for compounds with underpredicted clearance
- Apply derived concept to all Designathon compounds

Green: low toxic compounds (miss classified); **Black:** low toxic compounds; **Red:** toxic compounds; ***:** might show higher hepatic clearance



1) Varma MV, Steyn SJ, Allerton C, El-Kattan AF. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). Pharm Res. 2015 Dec;32(12):3785-802. doi: 10.1007/s11095-015-1749-4. Epub 2015 Jul 9. PMID: 26155985.



This project receives funding from the European Union's Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), and it is part of the ASPIS cluster.





@RISKHUNT3R

risk-hunt3r.eu